Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir-based regimens in routine practice for chronic HCV in China
CTR20201889Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ledipasvir, sofosbuvir, velpatasvir, sofosbuvir + velpatasvir + voxilaprevir in hepatitis C virus infection, sponsored by Gilead Sciences. Started Oct 2020; status: completed.
02
Drugs
ledipasvirsofosbuvirvelpatasvirsofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20201889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201889.